Precision Biosciences (DTIL) Enterprise Value (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Enterprise Value of -$28.3 million for Q1 2026, up 63.36% year-over-year from -$17.3 million in Q1 2025, and up 75.52% quarter-over-quarter from -$115.6 million in Q4 2025.
Precision Biosciences (DTIL) Enterprise Value (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Enterprise Value for 9 consecutive years, with -$28.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 63.36% year-over-year to -$28.3 million; the TTM figure through Mar 2026 stood at -$28.3 million (up 63.36% YoY), while the FY2025 annual figure was -$115.6 million, down 402.94% from the prior year.
- Enterprise Value grew to -$28.3 million in Q1 2026 per DTIL's latest filing, from -$115.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$22.6 million in Q2 2025 and bottomed at -$212.1 million in Q3 2022.
- Historically, Enterprise Value has averaged -$112.4 million across 5 years, with a median of -$116.7 million in 2023.
- On a YoY basis, Enterprise Value climbed as much as 81.74% in 2025 and fell as far as 402.94% in 2025.
- Precision Biosciences' Enterprise Value stood at -$189.6 million in 2022, then soared by 38.45% to -$116.7 million in 2023, then jumped by 80.3% to -$23.0 million in 2024, then sank by 402.94% to -$115.6 million in 2025, then surged by 75.52% to -$28.3 million in 2026.
- Business Quant data shows DTIL's Enterprise Value at -$28.3 million in Q1 2026, -$115.6 million in Q4 2025, and -$44.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Precision Biosciences | 228.28 Mn | 140.73 Mn | - | -87.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.55 Mn |
| Mar 31, 2026 | -28.29 Mn |
| Dec 31, 2025 | -115.59 Mn |
| Sep 30, 2025 | -44.87 Mn |
| Jun 30, 2025 | -22.56 Mn |
| Mar 31, 2025 | -77.22 Mn |
| Dec 31, 2024 | -22.98 Mn |
| Sep 30, 2024 | -101.20 Mn |
| Jun 30, 2024 | -123.57 Mn |
| Mar 31, 2024 | -137.77 Mn |
| Dec 31, 2023 | -116.68 Mn |
| Sep 30, 2023 | -122.23 Mn |
| Jun 30, 2023 | -137.79 Mn |
| Mar 31, 2023 | -158.13 Mn |
| Dec 31, 2022 | -189.58 Mn |
| Sep 30, 2022 | -212.05 Mn |
| Jun 30, 2022 | -184.14 Mn |
| Mar 31, 2022 | -116.22 Mn |
| Dec 31, 2021 | -143.66 Mn |
| Sep 30, 2021 | -160.47 Mn |